We are thrilled to share that BioInnovation Institute has awarded Sulis Therapeutics funding to support our lead project – taking the STING out of autoimmune diseases! A huge thank you to BII for believing in our vision. Claus Elsborg Olesen Richard Bethell Line Høgstrup Slemming Martin Roelsgaard Jakobsen #BII #Sulistherapeutics #biotech
Introducing Venture Lab cohort 7!💥 At BII, we're stoked to finally reveal the 12 start-ups that make up Venture Lab Cohort 7!🚀 💊💉In human health, we're welcoming Sulis Therapeutics, GlioRay, OvartiX, Analona Therapeutics, TROYA Therapeutics and Prenaital. 💻📲🏥⚛️In deep tech, we're welcoming DARERL ApS, ArcanaBio, and Phanofi. 🌍🌱In planetary health, we're welcoming NordicBlue ApS, Naturpladen ApS, and Mycoverse. "Spanning human health, deep tech, and planetary health, this cohort of start-ups has stood out against the many other applicants with their solid science, inspiring ideas, and drive to address current and future societal challenges. We're eager to support and enable these start-ups in bringing their research to market with our unique platform comprising knowledge, network, funding, and infrastructure to build successful companies," says Trine Bartholdy, Chief Business Officer at BII. Jens Nielsen, Bobby Soni Cathal J. Mahon Christian Brix Tillegreen, Antonia Zoric, Johanna Roostalu Tony Cheng-Fu Chang, Ditte Welner, Jon Strunge, Niels Bjerg Jensen, Helge Thisgaard, Andreas Ingemann Jensen, Sean Dean Lykke Harwood, Claus Elsborg Olesen, Richard Bethell, Martin Roelsgaard Jakobsen, Stasa Stankovic, Eva Hoffmann, Anna Murray, Tanja Danner, Anders Nymark Christensen, Martin G Tolsgaard, Kenny Erleben, Kristjan Gunnarsson, Hitesh Kumar Sahoo, Dagmawi Alemayehu Bekele, Mikkel Wandahl Pedersen #innovation #lifescience #deeptech #biobased #planetaryhealth #funding